Drug Profile
Research programme: cancer immunotherapies - Pionyr Immunotherapeutics
Latest Information Update: 10 Aug 2023
Price :
$50
*
At a glance
- Originator Centre for the Commercialization of Antibodies and Biologics
- Developer Pionyr Immunotherapeutics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 07 Aug 2023 Pionyr Immunotherapeutics has been acquired by Ikena Oncology
- 28 Feb 2021 No recent reports of development identified for research development in Cancer in USA
- 03 Apr 2017 Centre for the Commercialization of Antibodies and Biologics grants a non-exclusive license to Pionyr Immunotherapeutics for cancer immunotherapies